KRAS and adenocarcinoma: In contrast, the KRAS G12C mutation rate (13.3%) was in line with published data, which report G12C in approximately 12–14% of adenocarcinomas, confirming its relevance as a common actionable alteration in smoking-related NSCLC [31].